Biologic Success Starts with Drug Delivery
5 August 2026.
Drug delivery is reshaping biologics development, manufacturing, access and competition
Newsletter
US Missile-Defence Deals Reach Deeper into the Supply Chain
31 July 2026.
Washington targets missile-supply bottlenecks to expand PAC-3 and THAAD production
Ageing Rewrites Pharma Portfolio Strategy
29 July 2026.
Ageing reshapes pharma portfolios as access, evidence and delivery determine growth
UK Raises Its Combat Air Ambitions as Canada Joins GCAP
24 July 2026.
Canada joins GCAP as Britain accelerates its next-generation combat-air strategy
When Vaccine Policy Becomes Market Risk
22 July 2026.
Policy, platforms and manufacturing are reshaping global vaccine market opportunities
US Defence: Faster, Lower-Cost Production
17 July 2026.
US reforms target faster production, secure supply chains, lower costs
Cell & Gene Therapy Manufacturing: The Race to Scale
15 July 2026.
Manufacturing readiness now determines which cell and gene therapies scale
GCAP’s £4.6bn: Contract Tests Military Aviation
10 July 2026.
GCAP contract tests allied ambition, industrial capacity and combat-air delivery
UK’s £5bn Drone Plan Tests Defence Delivery
3 July 2026.
UK drone investment tests hybrid force design, funding and delivery
Healthcare Moves Home. Pharma Follows
1 July 2026.
Healthcare moves home as pharma’s commercial model shifts toward patients
The Next Pharma Challenge: Treatment Persistence
24 June 2026.
Patient persistence is becoming pharma’s next growth test after launch
Winning the Drone Age Is Now an Industrial Challenge
19 June 2026.
Low-cost drones force faster procurement and resilient defence supply chains
The Business of Prevention: Why Pharma Is Moving Upstream
17 June 2026.
Prevention-led pharma growth depends on earlier intervention, access and scale
Undersea Autonomy Moves From Trial to Delivery
12 June 2026.
Submarine delays push allies towards faster, riskier undersea autonomy bets
The Rise of the Micro-Blockbuster
10 June 2026.
Healthcare growth is shifting from standard treatments to personalised patient strategies
Women’s Health Trials: From the Margins to the Mainstream
3 June 2026.
Women’s health trials enter a more evidence-led, higher-value growth phase
AUKUS Moves from Strategy to Industrial Reality
29 May 2026.
AUKUS faces an industrial test as delivery risks intensify
Allied Defence Technology Moves from Development to Deployment
29 May 2026.
Defence procurement shifts toward proven, integrated and operationally ready technologies
The Next Phase of Vaccine Growth
27 May 2026.
Vaccines are shifting from prevention into platforms, oncology and manufacturing-led growth
Defence Plans Face The Funding And Readiness Test
22 May 2026.
Defence ambition now depends on funding, procurement speed and capability
